News Search Results
Apr 22, 2026, 11:22 ET Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals, Inc.
Apr 22, 2026, 11:00 ET H.I.G. Capital Announces the Sale of Celerion
integrated suite of services spanning data management, biostatistics, and clinical monitoring that supports a global base of pharmaceutical and biotechnology customers through its purpose-built clinical and laboratory infrastructure with facilities in Lincoln, Phoenix, Zurich, and Belfast.H.I.G.
More news about: H.I.G. Capital
Apr 22, 2026, 10:16 ET Digital Pathology Market to Reach USD 1,791.30 Million by 2030, Growing at 9.3% CAGR: Allied Market Research
principal clinical mandate(offer) of digital pathology systems. Drug Discovery is the most rapidly expanding application where pharmaceutical and biotechnology Companies harness digital platforms for quick biomarker identification, companion diagnostic development, and clinical trial tissue analysis. Rapidly
More news about: Allied Market Research
Apr 22, 2026, 10:01 ET Conductive Textiles Market to Reach US$ 8.5 billion by 2033, Expands Amid Smart Wearables and Advanced Material Innovation - Persistence Market Research
Ozone-Based Systems, Fogging & Electrostatic Sprayers, Others), Form (Wipes, Liquid, Spray), End Use (Healthcare Facilities, Pharmaceutical & Biotechnology, Medical Device Manufacturing, Academics & Research Institutes, Food & Beverage, Transportation, Commercial Buildings), and Regional Analysis
More news about: Persistence Market Research Pvt. Ltd.
Apr 22, 2026, 09:30 ET Made Scientific and Regenicin Announce Manufacturing Relationship to Advance NovaDerm Toward FDA Product Approval
/PRNewswire/ -- Made Scientific, Inc., a U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Regenicin, Inc., a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs,
More news about: Made Scientific, Inc.
Apr 22, 2026, 09:00 ET Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI
pioneer in AI-enabled target discovery, Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company recently published a comprehensive review that emphasizes key considerations in target selection, summarizes breakthroughs in the application
More news about: Insilico Medicine
Apr 22, 2026, 08:45 ET Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene
More news about: Anixa Biosciences, Inc.
Apr 22, 2026, 08:00 ET Deerfield Group Launches Prismatiq™, an Intuitive Field Enablement Platform Purpose-Built for Life Sciences
GroupDeerfield Group is a full-service integrated marketing, communications, and media agency providing innovative solutions for pharmaceutical, biotechnology, health tech, and consumer health companies. Deerfield's solutions are designed to meet the unique needs of healthcare organizations at all stages
More news about: Deerfield Group
Apr 22, 2026, 08:00 ET Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268
SAN FRANCISCO, April 22, 2026 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and
More news about: Thryv Therapeutics Inc.
Apr 22, 2026, 08:00 ET RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
breast cancer (TNBC)The positive NB data from studies undertaken by Penn State University's Jeremy Hengst and Apogee Biotechnology, and funded by the Beat Childhood Cancer Foundation and Four Diamonds, indicate that opaganib may enhance the therapeutic efficacy of the oxaliplatin
More news about: RedHill Biopharma Ltd.
Apr 22, 2026, 02:50 ET Samsung Biologics Reports First Quarter 2026 Financial Results
capacity and rapid response capabilities. In addition, the company announced a collaboration with Eli Lilly and Company to foster open innovation and biotechnology ecosystem development. These initiatives reflect the company's broader commitment to long-term industry collaboration and sustainable growth.The
More news about: Samsung Biologics
Apr 21, 2026, 21:30 ET Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten
More news about: Nektar Therapeutics
Apr 21, 2026, 19:31 ET MAHA ACTION WELCOMES BIOTECH PIONEER LOU REESE TO ITS BOARD OF DIRECTORS
America Healthy Again movement, today announced that Lou Reese has joined its Board of Directors. The appointment brings world-class expertise in biotechnology, global health innovation, and regenerative agriculture to the organization's leadership.
More news about: MAHA Action
Apr 21, 2026, 19:30 ET ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026
SEOUL, South Korea, April 21, 2026 /PRNewswire/ -- ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, today announced that results from its Phase 2 clinical study of VT-EBV-N have been
More news about: ViGenCell Inc.
Apr 21, 2026, 18:05 ET MEDP INVESTOR DEADLINE: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.The Medpace class action lawsuit alleges that defendants throughout the
More news about: Robbins Geller Rudman & Dowd LLP
Apr 21, 2026, 16:23 ET BioMarin Announces Board Leadership Transition
continue executing our strategy for patients around the world."About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Apr 21, 2026, 16:15 ET BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
product development."We're pleased to receive this recognition from INTERPHEX, one of the industry's leading forums for pharmaceutical and biotechnology innovation," said Roderick de Greef, CEO of BioLife Solutions. "This award is meaningful validation that CryoCase addresses a real need in the market.
More news about: BioLife Solutions, Inc.
Apr 21, 2026, 13:36 ET CollectiveMinds LLC Places Keith Meadors as Chief Commercial Officer at Genova Diagnostics
AI-powered technology to identify and place exceptional C-suite and senior leadership talent with speed and precision. The firm serves clients across biotechnology, biopharma, diagnostics, medical technology, and health technology sectors. Learn more at collectivemindsllc.com.About Genova DiagnosticsGenova
More news about: CollectiveMinds LLC
Apr 21, 2026, 12:15 ET TOSLA and Geltor Launch the First Vegan Signaling Collagen Liquid Supplement, Powered by PrimaColl®, a Type 21 Signaling Collagen
Signaling Collagen Shot in partnership with biotechnology pioneer,
More news about: TOSLA
Apr 21, 2026, 11:11 ET Alcami to Acquire Contract Packaging Organization Tjoapack
www.alcami.com.About TjoapackTjoapack is a global contract packaging organization (CPO) serving the pharmaceutical and biotechnology industries, with more than 35 years of experience in regulated pharmaceutical packaging. Founded in 1989 and headquartered in The Netherlands, the
More news about: Alcami
Apr 21, 2026, 09:36 ET L-Nutra CEO Dr. Joseph Antoun Named LA Times 'Life Sciences Visionary' for Pioneering Longevity as a Medical Discipline
and CEO, Joseph Antoun, MD, PhD, has been named a 2026 Life Sciences Visionary by LA Times Studios, recognizing leaders driving innovation across biotechnology and healthcare.
More news about: L-Nutra Inc.
Apr 21, 2026, 09:30 ET Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
April 21, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it is establishing its own dedicated clinic for
More news about: Northwest Biotherapeutics, Inc.
Apr 21, 2026, 09:30 ET Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
April 21, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it is establishing its own dedicated clinic for
More news about: Northwest Biotherapeutics, Inc.
Apr 21, 2026, 09:11 ET ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT
therapeutic response, and development of next-generation therapies. The platform will create a shared infrastructure for academic investigators, biotechnology companies, and clinical researchers to interrogate disease mechanisms, predict drug response in silico, validate targets, and develop tailored therapeutic
More news about: ReviR Therapeutics
Apr 21, 2026, 09:05 ET Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery
April 21, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry's first Longevity Board (Board). The initiative provides scientific oversight and
More news about: Insilico Medicine